Fulcrum Therapeutics/$FULC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Ticker
$FULC
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
45
ISIN
US3596161097
Website
FULC Metrics
BasicAdvanced
$386M
-
-$0.01
2.13
-
Price and volume
Market cap
$386M
Beta
2.13
52-week high
$10.13
52-week low
$2.32
Average daily volume
557K
Financial strength
Current ratio
28.711
Quick ratio
28.289
Long term debt to equity
2.567
Total debt to equity
3.547
Profitability
EBITDA (TTM)
-8.936
Gross margin (TTM)
28.73%
Net profit margin (TTM)
-0.64%
Operating margin (TTM)
-13.00%
Revenue per employee (TTM)
$1,780,000
Management effectiveness
Return on assets (TTM)
-2.74%
Return on equity (TTM)
-0.23%
Valuation
Price to revenue (TTM)
5.559
Price to book
1.69
Price to tangible book (TTM)
1.69
Price to free cash flow (TTM)
58.83
Free cash flow yield (TTM)
1.70%
Free cash flow per share (TTM)
12.17%
Growth
Revenue change (TTM)
3,087.25%
Earnings per share change (TTM)
-99.49%
3-year revenue growth (CAGR)
67.69%
3-year earnings per share growth (CAGR)
-84.90%
What the Analysts think about FULC
Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.
Bulls say / Bears say
Analysts have set an average 12-month price target of $8.63 for Fulcrum Therapeutics, suggesting potential upside from current levels. (defenseworld.net)
The company's net margin stands at an impressive 69.26%, indicating strong profitability and effective cost management. (benzinga.com)
Fulcrum Therapeutics has a low debt-to-equity ratio of 0.04, reflecting a prudent financial strategy and balanced approach to debt management. (benzinga.com)
The stock has experienced a significant decline of approximately 48.30% over the past year, raising concerns about its performance. (uspostnews.com)
Major investment firms, including BlackRock, have reduced their stakes in Fulcrum Therapeutics, potentially indicating decreased confidence. (gurufocus.com)
Several analysts have downgraded the stock to 'Hold' or 'Neutral' ratings, reflecting cautious sentiment about its future prospects. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
FULC Financial Performance
Revenues and expenses
FULC Earnings Performance
Company profitability
FULC News
AllArticlesVideos
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
GlobeNewsWire·4 weeks ago
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulcrum Therapeutics stock?
Fulcrum Therapeutics (FULC) has a market cap of $386M as of June 27, 2025.
What is the P/E ratio for Fulcrum Therapeutics stock?
The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of June 27, 2025.
Does Fulcrum Therapeutics stock pay dividends?
No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Fulcrum Therapeutics dividend payment date?
Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) has a beta rating of 2.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.